Glenmark Pharma shares slid nearly 5% after Q1 profit plunged 86% to ₹47 crore, hit by a ₹3,200 crore litigation charge. Revenue rose slightly to ₹3,264 crore, with India and US units posting gains, but Europe and emerging markets were weak. Management expects double-digit growth from Q2, led by oncology and respiratory launches.